Catalyst Reaches Enrollment Target For Its U.S. Phase II Cocaine Trial
Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, announced that it has reached its patient enrollment target in its Phase II trial evaluating CPP-109 for the treatment of cocaine addiction.
More: continued here
Filed under: Alcohol / Addiction / Illegal Drugs on January 11th, 2009